tbuckley/cabot-search huggingface dataset:
Poison
Authors: Jack Coulehan
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
This Week in JAMA
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Neurology
Authors: Hooman Kamel, New York, Bernard Chang, Dena Dubal, San Francisco, Ari Green, Michael Okun, Florida Gil, D Rabinovici, Kate Denevan, Nancy Hills, Cynthia Armand, Samuel Pleasure, Elan Guterman, Megan Richie, Maulik Shah, Carl Bazil, Alberto Espay, Eva Cincinnati, Ann Feldman, Nathalie Arbor, New Jetté, Ruchira York, Pooja Pittsburgh, Susan Ohio, Berkeley Landau, California Babak, B Navi, Daniel Ontaneda, Stanley Prusiner, Sonja Scholz, Maryland Kenneth, L Tyler, Paul Van Ness, Harold Wolff, H Merritt, Fred Plum, Maurice Van Allen, Robert Joynt, Roger Rosenberg, Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Iris Lo, Kevin Brown, Rebecca Langley, M Newman, Suzanne Walker, Connie Manno Senior, Sara Billings, Denise Steinhauser, Joe Wixted, Ahmed Avendano, Kim Boler, Rhonda Brown, Fin Carter, Michael Deegan, Daniel Degroot, Euwanaha Joiner-Smith, Joshua Lane, Cindy Rendlen, Ellen Yoshihara, Annissa Zak, Circulation Services, Julie Burton, Ronna Hewitt, Mary Sieck, Geneine Someren, Jamaal Vargas, Content Systems, Mike Bujewski, Nathan Mitre, Digital Production, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Maleeka Holden, Teri Hutchison, Dan Knowles, Joshua Lampinen, Natalie Marsh, Patricia Panek, Marla Seidell, La Son, Diggs Sledge, Julian Graphics, Joe Amft, James Collver, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Maria Giannini, Sasha Grossman, Judith Literskis, Teresa Omiotek, Michael Ryder, James Madara, Howard Bauchner, S Josephson
Journal: JAMA Neurology (2021)

The mission of JAMA Neurology is to publish scientifi c information primarily important for those physicians caring for people with neurologic disorders but also for those interested in the structure and function of the normal and diseased nervous system.These specifi c aims are (1) to make timely publication of original research of the nervous system, (2) to record observations of single patients or groups of patients that will provide new information and insights,(3) to report more basic research that is pertinent to the understanding of disease, (4) to introduce topics of practice, ethics, teaching, and history that are useful, and (5) to provide a forum for discussion on topics that may be controversial in this fi eld.This information will be published only after extensive peer review so that originality, clarity, and precision are ensured.
Ultrasound Surveillance to Detect Postoperative Venous Thrombosis
Authors: Douglas C. Bauer
Journal: JAMA (1992)

<h3>To the Editor.</h3> —Francis et al<sup>1</sup>suggest that warfarin therapy is more effective than external pneumatic compression in preventing proximal vein thrombosis after hip replacement surgery, but that it is less effective for the prevention of calf thrombosis. They advocate routine use of warfarin prophylaxis and suggest routine venography prior to discharge or extended use of warfarin to protect those patients who develop isolated calfthrombosis. However, orthopedic surgeons are reluctant to use perioperative anticoagulants.<sup>2</sup>Given this reluctance, alternative strategies might be developed based on the results of the study by Francis et al. One such alternative strategy would be the use of external pneumatic compression and postoperative surveillance with duplex ultrasound. Duplex ultrasound is highly sensitive and specific for asymptomatic proximal venous thrombosis following hip surgery.<sup>3,4</sup>Duplex ultrasound does not reliably detect isolated calf thrombosis, but serial ultrasound examinations have been used in other settings to detect
The HaemAtlas: Characterising Gene Expression in Differentiated Human Blood Cells
Authors: Nicholas A. Watkins, Marloes R. Tijssen, Arief Gusnanto, Bernard de Bono, Subhajyoti De, Diego Miranda-Saavedra, Will Angenent, Anthony Attwood, Cordelia Langford, Wendy N. Erber, Nicola Foad, Stephen F Garner, Augusto Rendon, Catherine Rice, Daphne Thijssen-Timmer, C. Ellen Van der Schoot, Frank Dudbridge, Sarah Teichmann, Bertie Gottgens, Willem H. Ouwehand
Journal: Blood (2008)
Hypoxemia is associated with mitochondrial DNA damage and gene induction. Implications for cardiac disease
Authors: M. Corral-Debrinski
Journal: JAMA (1991)

<h3>Objective.</h3> —Oxidative phosphorylation (OXPHOS) deficiency due to hypoxemia or other causes was hypothesized to increase oxygen radical generation, damage mitochondrial DNA (mtDNA), and reduce adenosine triphosphate synthesis, resulting in compensatory OXPHOS gene induction. Therefore, we investigated the levels of mtDNA damage and OXPHOS transcripts in normal and ischemic hearts, and then in other forms of heart disease. <h3>Design.</h3> —DNA was extracted from the heart and the levels of the common 4977 base pair mtDNA deletion were quantitated as an index for mtDNA damage. Total RNA was extracted from hearts and analyzed for OXPHOS transcript levels. <h3>Results.</h3> —In control hearts, the 4977 base pair mtDNA deletion appeared at age 40 years and reached a maximum deletion of 0.0035%. Much higher levels were found in ischemic hearts (0.02% to 0.85%), as well as in three of 10 cases with other types of heart disease (0.017% to 0.16%). The OXPHOS transcripts were increased in all diseased hearts. <h3>Conclusion.</h3> —Ischemic hearts have increased mtDNA damage and OXPHOS gene expression, suggesting that mtDNA damage is associated with OXPHOS deficiency. Oxidative phosphorylation defects may also play a role in some other forms of cardiac disease. (<i>JAMA</i>. 1991;266:1812-1816)
Uremia
Authors: Timothy W. Meyer, Thomas H. Hostetter
Journal: New England Journal of Medicine (2007)

The meaning of uremia, which refers to the illness accompanying kidney failure that is unexplained by derangements in extracellular volume, inorganic ion concentrations, or lack of known renal synthetic products, has changed. We now assume that uremic illness is due largely to the accumulation of organic waste products, not all identified, that are normally cleared by the kidneys. This review considers the pathogenesis and course of uremia.
Health care needs of homeless and runaway youths. Council on Scientific Affairs
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Natural history and prognostic factors of compensated cirrhosis secondary to non-alcoholic steatohepatitis in Catalonia
Authors: Octavi Bassegoda, Jesús Rivera, Serra Matamala Isabel, Rosa Mª Morillas, Teresa Broquetas, Mercedes Vergara Gómez, Adrià Rodríguez, Carlos Aracil, Sílvia Virolés, Jose A. Carrión, Albert Pardo, Miquel Serra, Pere Ginès, Isabel Graupera, Salvador Augustin
Journal: Journal of Hepatology (2020)
Monoclonal Antibodies
Authors: Betty Diamond
Journal: JAMA (1982)

<h3>Problems With Conventional Antisera</h3> The immune response plays an important role in man's resistance to infectious agents and has evolved to protect us from the many pathogens in our environment. The antibodies that are generated in response to foreign substances can also provide effective reagents for diagnosing and treating many diseases. However, since the natural role of such antibodies is to protect us from invading organisms, a major characteristic of the immune response is its heterogeneity, with many different antibodies being made in response to each antigen. This has complicated the use of antibodies as diagnostic reagents and therapeutic tools because most immune sera, whether raised in animals or man, are a mixture of hundreds to thousands of antibodies that differ from each other in their affinity and specificity. They also differ in their ability to carry out effector functions, such as the binding to macrophages, the fixation of complement,
Liver derived apoptotic microparticles as biomarkers to detect transition from simple steatosis to steatohepatitis in non-alcoholic fatty liver disease
Authors: Rocio Munoz Hernandez, Ángela Rojas, Sheila Gato Zambrano, Raquel Millan, Roció Gallego-Durán, Roció Montero-Vallejo, Maria Giraldez-Jimenez, Javier Ampuero, Manuel Romero Gomez
Journal: Journal of Hepatology (2020)
Correction:<i>Metastatic breast cancers have reduced immune cell recruitment but harbour increased macrophages relative to their matched primary tumors</i>
Authors: Emmanuel Normant, Ammar Adam, Marisa O Peluso, Caroline M Armet, Rachel W O’Connor, Benjamin H Lee, Andrew C Lake, Scott C Chappel, Jonathan A Hill, Vito J Palombella, Pamela M Holland, Alison M Paterson
Journal: Journal for ImmunoTherapy of Cancer (2020)

Correction: Metastatic breast cancers have reduced immune cell recruitment but harbour
366MO Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
Authors: S-W. Kim, D. Planchard, P-H. Feng, N. Karaseva, T.M. Kim, C.K. Lee, A. Poltoratskiy, N. Yanagitani, S. Powar, X. Huang, P. Howarth, P. Jänne, K. Kobayashi
Journal: Annals of Oncology (2020)
Treatment of tennis elbow. Use of a special brace
Authors: F. W. Ilfeld
Journal: JAMA (1966)

Tennis elbow or humeral epicondylitis is a minor ailment, but to a tennis player, a golfer, a gardener, or a skier, it can be a threat to his way of life. The entity is therefore worthy of prevention and treatment. This is a report on the study of 174 patients with epicondylitis of the elbow, with special reference to the effective treatment by an elbow brace.
Scientific Foundations of Surgery
Authors: John H. Wulsin
Journal: JAMA (1982)

Since the publication of the first edition of<i>Scientific Foundations of Surgery</i>in 1967, the initial work succeeded so well that a series of 15<i>Scientific Foundations</i>volumes has appeared covering various specialties, such as neurology, anesthesia, and dentistry. While the original intent of the editors centered on having clinical authors discuss the basic research and pathophysiological principles underlying clinical problems ("a book by surgeons for surgeons"), subsequent editions have relied more on acknowledged investigators in pertinent fields of medical science. Although the first editors and most of the contributors hold positions in universities and hospitals throughout the British Commonwealth, the coeditor of the current edition, Dr James Hardy of the University of Mississippi, has selected an eminent group of American surgeons as contributors, most notably to the sections dealing with "Immunology and Transplantation" and with the "Liver, Gallbladder and Ducts." Compared with the second edition, this work has been
PHOTOTHERAPY AND SENSIBILIZATION.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A LIBRARY FOUNDED BY DR. ROBERT BATTEY.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Contents page + Editorial Board
Authors: Alexei Verkhratsky, Mark Mattson, Emil Toescu, Patrick Mantyh, Stephen Hunt, Juan Mena-Segovia, J Bolam, Peter Magill, Stuart Maudsley, Bronwen Martin, Gustavo Barja, Patrick Hof, John Morrison, Philip Landfield, Angela Bodles, Steven Barger, Bruce Teter, Caleb Finch, Thomas Perls, Alice Witney, Alan Wing, Jean-Louis Thonnard, Allan Smith Trendsin, Sian Lewis, Heather Yeomans, Kate Burke, Manager Moulton
Journal: Trends in Neurosciences (2004)
International Conference on Malignant Lymphomas
Journal: JNCI Journal of the National Cancer Institute (1980)

Journal Article International Conference on Malignant Lymphomas Get access JNCI: Journal of the National Cancer Institute, Volume 65, Issue 5, November 1980, Page 1198, https://doi.org/10.1093/jnci/65.5.1198-a Published: 01 November 1980
Prediction of 10yr distant recurrence (DR) using the Prosigna (PAM50) assay in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone.
Authors: Anne-Vibeke Lænkholm, Maj-Britt Jensen, Jens Ole Eriksen, Torben Kibøll, Birgitte Bruun Rasmussen, Ann S. Knoop, Sean Ferree, Taryn Haffner, Carl Schaper, Bent Ejlertsen
Journal: Journal of Clinical Oncology (2015)

546 Background: The Prosigna (PAM50) risk of recurrence (ROR) score has been validated in two randomized clinical trials to predict 10yr DR in EBC patients treated with ET alone. Here we examine the value of PAM50 for predicting risk of DR in a comprehensive nationwide cohort from Denmark consisting of all postmenopausal women diagnosed with HR+ EBC allocated to 5yr of ET alone. Methods: Using the population based DBCG database FFPE primary tumor blocks and follow-up data were collected from all patients diagnosed from 2000-2003 (N = 2749) who by nationwide guidelines were allocated to 5yr of ET alone. PAM50 was conducted using the NanoString nCounter Analysis System. Univariate and multivariate analyses tested the ability of PAM50 to predict DR. Patients were categorized as Low, Intermediate, or High risk based upon pre-specified ROR cutoffs varied by number of positive nodes. Results: Blocks from 2749 patients were identified and data from 2722 samples (1256 N0, 1466 N1) were included in the analysis (99%). Median follow-up was 9.25yr. High risk patients (n = 1200) had a DR risk of 20.8% [95%CI: 18.3-23.4] at 10 years, compared to 4.3% [2.9-6.2] for Low risk patients (n = 733). These figures were consistent across nodal status. Adding ROR to a Fine and Gray's proportional sub-hazards model containing clinical and pathological variables significantly improved the model (likelihood ratio: p < 0.0001; HR for a 20-point change in ROR = 1.7 [1.5-1.9]. Luminal B tumors (N = 977, DR risk = 18.0% [15.4-20.9]) and Her2-enriched tumors (N = 203, DR risk = 27.7% [21.5-34.3]) had a significantly worse outcome than Luminal A (N = 1515, DR risk = 7.7% [6.2-9.3]), both p < 0.0001. Conclusions: To our knowledge, this is the first genomic study of breast cancer on a comprehensive nationwide population. Prosigna (PAM50) improved the prediction of outcome over and above standard clinical and pathological variables in this DBCG cohort devoid of physician selection bias. PAM50 can reliably identify patients in a real world setting who may be spared overtreatment with chemotherapy.
Textbook of Physiology.
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
xxx
Authors: C. Tarella, M. Zanni, A. Rambaldi, F. Benedetti, R. Passera, A. M. Gianni
Journal: Journal of Clinical Oncology (2007)

8123 Background: The high-dose sequential (HDS) chemotherapy approach, including early dose-intensification and autograft with peripheral blood progenitor cells (PBPC), was introduced several years ago (Gianni &amp; Bonadonna, 1989); subsequently, it has been broadly used in the management of both non-Hodgkin s (NHL) and Hodgkin s Lymphoma (HL). The outcome of a large series of lymphoma patients treated with the HDS approach at 10 GITIL Centers is reported. Methods: Data have been collected on 1,266 patients, who received either the original or slightly modified HDS regimens. There were 213 HL and 1,053 NHL (630 intermediate/high-grade, 423 low-grade); median age was 46 yrs. Overall, 671 (53%) patients had refractory/relapsed disease, 595 (47%) were at diagnosis. Most patients were autografted with PBPC; 158 (12%) patients did not undergo autografting due to toxicity, disease progression or poor harvests. Results: Overall, 1,013 (80%) patients reached Complete Remission (CR) following HDS. As to December 2006, 93 (7%) patients died for early/late toxicities, 328 (26%) died for lymphoma, 844 are known to be alive. At a lead follow-up of 18 years, and a median follow-up of 5 yrs, the 5-yr Overall Survival (OS) projection is 64% (S.E.: 2%). The long-term survival was quite favorable in patients achieving a Complete Remission (CR), with a 5-yr OS projection of 76%. The prolonged OS in patients achieving CR was consistent in all lymphoma subtypes, i.e. both low and high-grade NHL (5-yr OS: 77% in both), and HL (5-yr OS: 72%). Patients at diagnosis had a significantly better outcome compared to patients treated for relapsed/refractory disease, again CR achievement was associated with prolonged survival in both subgroups (82% and 69%, respectively, at 5 yrs.). On multivariate Cox survival analysis, CR achievement was the most powerful predictor of long-term survival (HR 0.13, c.i.: 0.10–0.17). Lastly, achieving substantial tumor reduction before autografting had a major influence on the clinical outcome. Conclusions: 1. the HDS program is feasible in a multicenter setting; 2. the long-term outcome is well influenced by the CR status after HDS; 3. the influence of CR achievement on the long-term survival holds true in all lymphoma subtypes, including indolent lymphomas; 4. an adequate pre-autograft tumor debulking may contribute to a favorable long-term outcome. [Table: see text]